肿瘤细胞治疗研究
英文原题：The Progress and Prospects of Immune Cell Therapy for the Treatment of Cancer.
免疫细胞疗法作为一种革命性的治疗方式，显著改变了癌症治疗格局。
免疫细胞疗法作为一种革命性的治疗方式，显著改变了癌症治疗格局。它是一种特殊的免疫治疗形式，利用活的免疫细胞作为治疗试剂来治疗癌症。与传统药物不同，细胞疗法被视为“活体药物”，这些产品目前需要定制化并依赖先进的制造技术。尽管嵌合抗原受体（CAR）-T细胞疗法在血液系统恶性肿瘤治疗领域受到了业界极大关注，但其在实体瘤治疗中的效果往往受限，这促使了替代性免疫细胞疗法的出现。TIL（肿瘤浸润淋巴细胞）细胞疗法、细胞因子诱导的杀伤（CIK）细胞疗法、树突状细胞（DC）疫苗以及DC/CIK细胞疗法旨在利用人体自身的防御机制来靶向并清除癌细胞，且通常副作用或风险较少。另一方面，诸如CAR-T（CAR-T）细胞、T细胞受体（TCR）-T、嵌合抗原受体自然杀伤（CAR-NK）或CAR-巨噬细胞（CAR-M）等细胞疗法通常使用自体干细胞、同种异体或异种细胞，或基因修饰细胞，这些需要更高水平的操作，并被视为高风险。这些高风险细胞疗法通常在肿瘤靶向和信号转导方面具有特殊特征，能够触发新的抗肿瘤免疫反应。近年来，在抗肿瘤机制、细胞治疗产品设计和技术创新方面的基础与临床研究均取得了显著进展。随着技术的快速整合和高创新格局的形成，未来的关键发展方向已经显现。为满足细胞治疗技术在癌症治疗中的发展需求，本研究全面系统地探讨了免疫细胞疗法的技术创新与临床进展。基于免疫细胞疗法的治疗机制和方法学特征，我们分析了这些疗法的主要技术优势及临床转化风险。我们还分析并预测了应用前景，为相关企业在研发方向选择上做出明智决策提供了必要的信息参考。
Immune cell therapy as a revolutionary treatment modality, significantly transformed cancer care. It is a specialized form of immunotherapy that utilizes living immune cells as therapeutic reagents for the treatment of cancer. Unlike traditional drugs, cell therapies are considered "living drugs," and these products are currently customized and require advanced manufacturing techniques. Although chimeric antigen receptor (CAR)-T cell therapies have received tremendous attention in the industry regarding the treatment of hematologic malignancies, their effectiveness in treating solid tumors is often restricted, leading to the emergence of alternative immune cell therapies. Tumor-infiltrating lymphocytes (TIL) cell therapy, cytokine-induced killer (CIK) cell therapy, dendritic cell (DC) vaccines, and DC/CIK cell therapy are designed to use the body's natural defense mechanisms to target and eliminate cancer cells, and usually have fewer side effects or risks. On the other hand, cell therapies, such as chimeric antigen receptor-T (CAR-T) cell, T cell receptor (TCR)-T, chimeric antigen receptor-natural killer (CAR-NK), or CAR-macrophages (CAR-M) typically utilize either autologous stem cells, allogeneic or xenogeneic cells, or genetically modified cells, which require higher levels of manipulation and are considered high risk. These high-risk cell therapies typically hold special characteristics in tumor targeting and signal transduction, triggering new anti-tumor immune responses. Recently, significant advances have been achieved in both basic and clinical researches on anti-tumor mechanisms, cell therapy product designs, and technological innovations. With swift technological integration and a high innovation landscape, key future development directions have emerged. To meet the demands of cell therapy technological advancements in treating cancer, we comprehensively and systematically investigate the technological innovation and clinical progress of immune cell therapies in this study. Based on the therapeutic mechanisms and methodological features of immune cell therapies, we analyzed the main technical advantages and clinical transformation risks associated with these therapies. We also analyzed and forecasted the application prospects, providing references for relevant enterprises with the necessary information to make informed decisions regarding their R&D direction selection.
MEMBER ACCOUNT
登录成功会直接打开下一页。
